Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO versus SEVELAMER CARBONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO versus SEVELAMER CARBONATE.
PHOSLO vs SEVELAMER CARBONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
Sevelamer carbonate is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. It also binds bile acids and may reduce LDL cholesterol.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
Adults: 800 to 1600 mg orally three times daily with meals, titrated according to serum phosphorus targets.
None Documented
None Documented
Not applicable; minimal systemic absorption, local gastrointestinal action
Not applicable. Sevelamer carbonate is not systemically absorbed and thus has no measurable plasma half-life. Its pharmacological effect correlates with gastrointestinal transit time, which is typically 24-48 hours.
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Sevelamer carbonate is not absorbed systemically; it acts locally in the gastrointestinal tract. Excretion is entirely fecal, with no renal or biliary elimination. The polymer is excreted unchanged in the feces.
Category C
Category A/B
Phosphate Binder
Phosphate Binder